Focusing on scientific discovery and innovation to save human lives
Cancer is the second most common cause of death in the US, exceeded only by heart disease. One of every four
deaths in the United States is due to cancer. The American Cancer Society estimates that in 2014,
about 1,665,540 Americans were diagnosed with invasive cancer, and 585,720
Americans died of this disease. The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. The National Institutes of Health (NIH) estimates overall costs of cancer care in 2010 at $263.8 billion. Currently used cancer drugs such as chemotherapeutic agents and monoclonal antibodies have limitations due to their toxicities and are ineffective against tumors with drug resistance. Thus, there is an urgent need for more potent, targeted and safer cancer therapeutics. Oncotherapy Solutions, a new biotechnology company is utilizing its previous expertise in preclinical drug development and delivery to design and test new pipeline of targeted, potent, stable and safer drug conjugates for the treatment of prostate, ovarian, endometrial, breast, colon, pancreatic and lung cancers.
The company currently has three preclinical programs:
The first program is focused on the development of novel, potent and safer drug conjugates carrying siRNAs or new chemotherapeutic agents. We are currently conducting proof of concept in-vitro preclinical studies of these drug conjugates on prostate and ovarian cancer cells and planning to start in-vivo studies soon. Our long term goal is to move these cost-effective drug conjugates to the clinic as frontline cancer therapeutics to replace standard chemotherapy which suffers from high toxicity and low potency in drug-resistant cancers.
The second program is dedicated to the development of novel kinase inhibitors for the treatment of breast and colon cancers. We are in the process of testing these novel kinase inhibitors as small molecule or targeted nanoparticle formulations in-vitro on multiple breast and colon cancer cell lines. Lead kinase inhibitor formulations will be further tested in-vivo in animal models bearing human breast or colon xenografts.
The third program is focused on the development of new cost-effective compounds with ability to activate and prime cytotoxic T cells and natural killer cells to recognize and destroy cancer cells. This immunotheapy program is currently on hold until appropriate funds are secured.